文献速递癫痫

PF-06372865治疗光敏性癫痫的2a期交叉研究

Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.
PubMed 文献 · Neurology · 2019-03-15

这项2a期随机双盲四周期交叉研究纳入7例基线间歇闪光刺激(IPS)诱发光阵发性反应的受试者,评估GABAA受体α2/3/5亚型正向变构调节剂PF-06372865的单次剂量(17.5和52.5 mg)与劳拉西泮2 mg及安慰剂对比。结果显示两个剂量均显著降低标准化光敏范围(SPR),程度与劳拉西泮相似,6/7例受试者SPR完全抑制,药物安全耐受。

要点

  • PF-06372865两个剂量均显著降低光敏性癫痫模型的光敏范围。
  • 6/7例受试者在PF-06372865或劳拉西泮后光敏反应完全抑制。
  • 该药安全耐受,支持进一步研究其抗癫痫特性。

核心结论

  • PF-06372865在光敏性癫痫模型中表现出高度稳健的抗惊厥活性,支持进一步研究其抗癫痫特性。

研究设计与样本

  • 2a期随机双盲四周期交叉研究,纳入7例基线IPS诱发光阵发性反应的受试者。
  • 受试者接受单次剂量PF-06372865 17.5 mg和52.5 mg、劳拉西泮2 mg及安慰剂。

主要发现

  • 两个剂量PF-06372865均较安慰剂显著降低SPR,程度与劳拉西泮相似。
  • 6/7例受试者在PF-06372865或劳拉西泮后SPR完全抑制。
  • PF-06372865安全且耐受良好。

关键数值与推荐

  • 主要终点为受试者最敏感眼条件下SPR在所有时间点的平均最小二乘均值变化。
  • SPR在筛选期、给药前及给药后1、2、4、6小时记录。

临床怎么用

  • PF-06372865作为α2/3/5亚型选择性GABAA正向变构调节剂,在光敏性癫痫模型中显示抗惊厥活性。
  • 该结果支持进一步研究PF-06372865的抗癫痫特性,但尚未确立临床用药方案。

局限性

  • 研究样本量小(7例),为2a期概念验证研究。
  • 仅评估单次剂量,未提供长期疗效和安全性数据。
  • 证据等级为Class II。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABAA receptors with minimal activity at α1-containing receptors, which are believed to mediate many of the adverse events associated with benzodiazepines, in the epilepsy photosensitivity model as a proof-of-principle of efficacy. METHODS: Seven participants with a photoparoxysmal response to intermittent photic stimulation (IPS) at baseline were randomized in a double-blind, 4-period cross-over study examining single doses of 17.5 and 52.5 mg PF-06372865, 2 mg lorazepam (active control), and placebo. Standardized photosensitivity ranges (SPRs) to IPS were recorded at screening, predose, and 1, 2, 4, and 6 hours postdose. The primary endpoint was the average least squares mean change in the SPR in the participant's most sensitive eye condition, across all time points. RESULTS: Both doses of PF-06372865 produced a marked and statistically significant mean reduction in SPR compared to placebo, which was similar in degree to lorazepam. There was complete suppression of SPR in 6/7 participants following PF-06372865 or lorazepam administration. PF-06372865 was safe and well-tolerated. CONCLUSION: PF-06372865 demonstrated highly robust efficacy. This demonstrates anticonvulsant activity of a novel α2/3/5-subtype selective GABAA PAM in humans. Further study of the antiepileptic properties of PF-06372865 is warranted. CLINICALTRIALSGOV IDENTIFIER: NCT02564029. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for people with a stable photoparoxysmal response to intermittent photic stimulation, PF-06372865 reduces the SPR.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gurrell R, Gorman D, Whitlock M, et al. Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator. Neurology. 2019. PMID: 30877186. doi:10.1212/WNL.0000000000007271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。